Tiziana Life Sciences LtdTLSA
Price$1.11

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $0TTM through 31 Dec 2024
Net Income -$11.9MTTM through 31 Dec 2024
Free Cash Flow -$1.5MTTM through 31 Dec 2024

Margins

Current
Gross Margin0.0%

Returns

-353.8%ROE
-160.0%ROA

Balance Sheet Health

Debt / Equity0.00x
Current Ratio0.76x
Net Debt-$4Mnet cash position
Cash & Equivalents$3.7M

Quality Metrics

Piotroski F-Score2 / 9

Multi-Year Trend

Diluted EPS
'18'19'20'21'22'23'24
FY2024: $-0.11

Dividend

No dividend

Segment Performance

SegmentRevenueYoYOutlook
Biotechnology R&D$00.0%
View details

Topline data from the Phase 2a INFORM-MS trial expected in late Q3 2026.

All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.